The SMART ART Study
A Sequential Multiple Assignment Randomized Trial of Scalable Interventions for ART Delivery in South Africa: the SMART ART Study
2 other identifiers
interventional
874
1 country
1
Brief Summary
The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with detectable viral load and/or not engaged in care.The types of differentiated service delivery (DSD) that will be examined in this study are incentives, community-based ART, and home delivery. The study plans to enroll up to 900 participants-people living with HIV and who are eligible for ART and living in KwaZulu-Natal, South Africa. The study aims to maximize the proportion of ART eligible persons living with HIV who achieve viral suppression at 18 months. The study will also evaluate the preferences of clients and providers for differentiated service delivery, and evaluate the cost effectiveness of adaptive HIV treatment for those who are not engaged in care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable hiv
Started Nov 2021
Typical duration for not_applicable hiv
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 16, 2021
CompletedFirst Posted
Study publicly available on registry
October 22, 2021
CompletedStudy Start
First participant enrolled
November 2, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 3, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 3, 2025
CompletedJanuary 12, 2026
January 1, 2026
3.7 years
September 16, 2021
January 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Viral suppression at 18 months
The primary outcome is viral suppression at 18 months among the combined group of persons living with HIV who have detectable viral load and persons not engaged in care at enrollment.
18 months
Secondary Outcomes (4)
Retention in Care
12 months
Time to ART initiation
6 months
Engagement in care
18 months
Comparison to viral suppression and retention outcomes from similar local clinics
18 months
Study Arms (6)
Best clinic practices
NO INTERVENTIONParticipants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)
Best clinic practices plus lottery incentives
EXPERIMENTALParticipants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)
Randomized from best clinic practices to smart lockers
EXPERIMENTALSecond randomization into community ART through the use of smart lockers
Randomized from best clinic practices to home delivery
EXPERIMENTALSecond randomization into home ART delivery
Randomized from best clinic practices plus lottery incentives to smart lockers
EXPERIMENTALSecond randomization into community ART through the use of smart lockers
Randomized from best clinic practices plus lottery incentives to home delivery
EXPERIMENTALSecond randomization into home ART delivery
Interventions
Home ART refill and monitoring, adherence support
Decentralized ART refills and monitoring, adherence support
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
Continue with best clinic practices
Eligibility Criteria
You may qualify if:
- Must be 18 years or older
- Able and willing to provide informed consent for study procedures
- Must self report that they will reside in the study community for the duration of follow-up
- Living with HIV and eligible for ART by national guidelines, have a detectable viral load greater than the lower limit of detection and/or not engaged in care, and are stable clinically (CD4\>100 cells, no moderate/severe screening laboratory abnormalities for kidney function i.e. eGFR \>50 mL/min/1.73m2, not receiving treatment for active tuberculosis or other opportunistic infections).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Human Sciences Research Council Sweetwaters
Sweetwaters, KwaZulu-Natal, South Africa
Related Publications (1)
van Heerden A, Szpiro A, Ntinga X, Celum C, van Rooyen H, Essack Z, Barnabas R. A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa: the SMART ART study. Trials. 2023 Jan 17;24(1):32. doi: 10.1186/s13063-022-07025-x.
PMID: 36647092RESULT
Study Officials
- PRINCIPAL INVESTIGATOR
Ruanne V Barnabas, DPhil
University of Washington
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 16, 2021
First Posted
October 22, 2021
Study Start
November 2, 2021
Primary Completion
July 3, 2025
Study Completion
July 3, 2025
Last Updated
January 12, 2026
Record last verified: 2026-01